CAJ | 학술논문

由于HIV和HBV具有相同的传播途径，增加了HIV/HBV合并感染的风险。二种病毒相互促进彼此基因的转录复制，可能发生基因重组而产生新的变异，影响治疗效果。抗HIV和HBV的药物中包含了相同的核苷（酸）类似物（如拉米夫定、恩曲他滨、恩替卡韦和替诺福韦酯），如果不能正确使用这些具有双重抗病毒活性的药物，就很可能诱导HIV或HBV耐药株的出现以及抗病毒药物之间的交叉耐药，对AIDS和慢性乙型肝炎的预后带来严重的影响。本文对HIV/HBV合并感染的研究进展进行综述。
유우HIV화HBV구유상동적전파도경，증가료HIV/HBV합병감염적풍험。이충병독상호촉진피차기인적전록복제，가능발생기인중조이산생신적변이，영향치료효과。항HIV화HBV적약물중포함료상동적핵감（산）유사물（여랍미부정、은곡타빈、은체잡위화체낙복위지），여과불능정학사용저사구유쌍중항병독활성적약물，취흔가능유도HIV혹HBV내약주적출현이급항병독약물지간적교차내약，대AIDS화만성을형간염적예후대래엄중적영향。본문대HIV/HBV합병감염적연구진전진행종술。
The same routes of transmission of HIV and HBV increase the risk of HIV/HBV co-infection. Both kinds of the viruses interact by promoting each other's gene transcription and replication, so genetic recombination among them may produce ad-ditional mutations and affect the treatment effect. Some nucleos (t)ide analogues such as lamivudine, emtricitabine, entecavir and tenofovir, have both anti-HIV and anti-HBV activities, and it is likely to induce the emergence of resistant strains of HIV and/or HBV and cross resistance of the antiviral agents if they are not properly used, which may lead to serious effects on the prognosis of AIDS and chronic hepatitis B. This article reviews the research progress of HIV/HBV co-infection.